First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Summary

This is Phase I first-in-human trial evaluating the safety, tolerability, immunogenicity, and pharmacogenomics of LQ036 via inhalation and IV infusion. The study will be divided into 4 parts: Single Ascending Dose, Multiple Ascending Dose, and Intra Venous with a target of 88 healthy volunteers and 30 patients with mild Asthma.

Timeline

Start

2021-09-06

Primary completion

2023-03-02

Completion

2023-03-09

Outcome

Outcome not reported

Stopped: “Copmeletion of Part A SAD cohorts, sponsor cancelled Part B-D cohorts”

Drugs

Indications